CNS patients who depend most on consistent drug delivery are often the least equipped to maintain it through oral dosing. GI dysfunction and motor impairment disrupt absorption and administration precisely when therapeutic concentration matters most. The clinical rationale for non-oral delivery has been understood for years. What’s changed is the approval record, and it now gives programs a framework to act on.
Why Oral Dosing Fails the CNS Population
GI Dysfunction and Absorption Variability
GI dysmotility is a documented feature of several high-prevalence CNS conditions, Parkinson’s and Alzheimer’s disease chief among them. In Parkinson’s, delayed gastric emptying produces plasma concentration variability that shortens the therapeutic window and drives on/off cycling that makes disease management unpredictable. A patient takes the tablet on schedule, but systemic absorption depends on gastric motility at the time of dosing, and no dosing adjustment accounts for that variability.
Mucosal delivery and transdermal routes bypass that variable entirely. The same molecule, delivered by a different route, produces a plasma concentration profile that isn’t contingent on GI function.
Motor Impairment and Administration
The absorption problem is only part of the picture. There’s an administration problem layered on top of it that formulation alone can’t solve, and in CNS populations, the two compound each other.
A Parkinson’s patient in an off episode needs motor coordination to open a pill bottle, handle water, and manage a tablet. That coordination is precisely what the episode removes. The medication that would break the episode is the one they physically cannot take. That’s not an adherence failure. It’s an access failure, and no amount of dosing optimization addresses it.
Acute psychiatric settings present a different version of the same problem. A patient in distress cannot reliably self-administer an oral dose, and injectable delivery requires trained personnel most patients don’t have access to at home. Thin films work around both constraints, requiring neither the dexterity of oral dosing nor the personnel requirements of injection.
For these populations, the absorption failure and the administration failure aren’t incidental. They’re features of the condition itself. The reformulation programs that have gained regulatory traction address both.
How 505(b)(2) Makes CNS Reformulation Viable
Recognizing that a molecule needs a different delivery format solves half the problem. The reformulation still needs a regulatory pathway that doesn’t require re-proving safety and efficacy from a clean slate.
CNS reformulations of approved molecules don’t require a full de novo clinical program. Under 505(b)(2), a sponsor references the safety and efficacy data already in the regulatory record for the original molecule and focuses product development on demonstrating that the new format achieves an acceptable pharmacokinetic profile for the target indication.
In practice, that means PK bridging studies establishing bioequivalence or a well-characterized difference in the absorption profile, supported by regulatory documentation focused on the delivery change rather than relitigating the underlying therapeutic case.
For a molecule with an established CNS safety record, the scope is substantially narrower than that of a novel-molecule program.
What the FDA Approval Record Has Established
The 505(b)(2) pathway has produced a consistent approval pattern across non-oral CNS formats: an established molecule, a delivery problem oral dosing could not solve, and a regulatory scope focused on the reformulation rather than the underlying therapeutic case. What differs between formats is the clinical problem each one addresses.
What the OTF Record Has Accomplished
For sublingual and buccal OTF programs targeting episodic CNS events, the endpoint framework depends on two variables: the onset profile relative to the acute event, and whether the route of administration is viable for the patient population at the moment the dose is needed.
A patient in a motor event or acute psychiatric distress cannot reliably self-administer an oral dose. The endpoint framework developed for mucosal delivery reflects that clinical reality. PK bridging for these programs measures mucosal absorption and bioavailability directly, rather than the GI transit-time and fed-state variables that bridging studies for oral tablets have to account for.
READ MORE: Sublingual Thin Films: Breakthrough Bioavailability without the Needle
Secuado (Asenapine Transdermal)
Chronic CNS transdermal programs answer a different regulatory question than acute OTF programs do. The question isn’t whether the format can act fast enough. It’s whether it can sustain therapeutic plasma levels and support adherence over the full course of chronic treatment. The endpoint framework for transdermal delivery centers on steady-state concentration and dosing consistency, the same variables that determine outcomes in the conditions these products treat.
Where the OTF record addresses acute episodic events, Secuado addressed a chronic one. Approved in 2019 for schizophrenia, it established that steady-state plasma concentration and adherence are crucial for a chronic CNS transdermal program.
For programs with antipsychotic molecules in late-stage development or approaching patent expiry, it remains the most relevant regulatory precedent available.
Exelon Patch (Rivastigmine)
The Exelon Patch extended the transdermal template to dementia, where the primary variable in administration is not the patient. It’s the caregiver. Approved for Alzheimer’s disease, it simplified a daily dosing routine that otherwise depends on a patient population with progressive cognitive impairment, anchored the transdermal cholinesterase inhibitor template, and remains the primary reference point for caregiver-administered chronic CNS transdermal delivery.
Both approvals share the same pattern: a molecule with an established safety record, a delivery problem oral dosing could not solve, and a 505(b)(2) pathway that made the reformulation program viable. Today’s CNS drug delivery pipeline follows that same design.
Where OTF and Transdermal Are Active in CNS
Acute and episodic conditions favor OTF, where speed of onset and administration reliability are the primary clinical requirements. Chronic conditions favor transdermal, where steady-state concentration and dosing consistency determine therapeutic outcomes.
OTF: Acute and Episodic CNS Events
- Migraine: Triptan reformulations target first-pass bypass and rapid mucosal absorption, two properties oral delivery reliably undermines during an acute event.
- Seizure rescue: Benzodiazepine programs require fast onset and dependable administration when oral dosing is not clinically viable.
- Parkinson’s off episodes: Both the pharmacokinetic and administration profiles point away from oral delivery. Mucosal absorption bypasses the gastric variability that makes tablet dosing unreliable when it matters most.
- Palliative care: A growing segment where progressive loss of swallowing capacity makes non-oral administration a clinical requirement, not a preference.
Transdermal: Chronic CNS Conditions
- Alzheimer’s disease: Cholinesterase inhibitor programs benefit from transdermal delivery for pharmacokinetic consistency and caregiver administration, with the Exelon Patch providing an established regulatory template.
- Schizophrenia: Antipsychotic programs continue to generate transdermal development interest, where consistent plasma levels reduce the adherence variability that drives relapse.
- ADHD: Stimulant reformulations target steady-state delivery to reduce plasma-level variability associated with oral dosing over a dosing interval.
READ MORE: What Pharmaceutical Teams Miss about Adhesive Systems in Transdermal Delivery
Matching the Indication to the Format
That decision is harder than it looks, and the partner you make it with matters. A CDMO with depth in only one format will orient your program toward that format regardless of what the indication requires. The delivery approach reflects the partner’s capabilities rather than the patient’s clinical needs.
A partner with genuine capabilities across both formats evaluates the indication first. The clinical problem defines the format, and the molecule’s pharmacokinetic profile determines the formulation strategy from there.
ARx has conducted that evaluation across OTF and transdermal programs, including a tech transfer that advanced a stranded buccal program. With direct CNS formulation experience across both platforms and capabilities spanning early development through commercial manufacturing, the team can assess where your molecule fits and what the path forward looks like.
Evaluating a CNS reformulation program? Connect with the ARx team to discuss your molecule and start a feasibility assessment.